Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00130442
Recruitment Status : Completed
First Posted : August 15, 2005
Last Update Posted : March 31, 2016
Progen Pharmaceuticals
Information provided by (Responsible Party):
Medigen Biotechnology Corporation

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : October 2010
  Study Completion Date : October 2010